CA3178878A1 - Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain - Google Patents

Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain

Info

Publication number
CA3178878A1
CA3178878A1 CA3178878A CA3178878A CA3178878A1 CA 3178878 A1 CA3178878 A1 CA 3178878A1 CA 3178878 A CA3178878 A CA 3178878A CA 3178878 A CA3178878 A CA 3178878A CA 3178878 A1 CA3178878 A1 CA 3178878A1
Authority
CA
Canada
Prior art keywords
once
days
transdermal
patch
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3178878A
Other languages
English (en)
French (fr)
Inventor
Fotios M. Plakogiannis
Tamanna LATHER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pike Therapeutics Inc
Original Assignee
Pike Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pike Therapeutics Inc filed Critical Pike Therapeutics Inc
Publication of CA3178878A1 publication Critical patent/CA3178878A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3178878A 2020-04-20 2021-04-20 Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain Pending CA3178878A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063012428P 2020-04-20 2020-04-20
US63/012,428 2020-04-20
PCT/IB2021/000261 WO2021214545A1 (en) 2020-04-20 2021-04-20 Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain

Publications (1)

Publication Number Publication Date
CA3178878A1 true CA3178878A1 (en) 2021-10-28

Family

ID=78270322

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3178878A Pending CA3178878A1 (en) 2020-04-20 2021-04-20 Transdermal and/or topical pharmaceutical formulations comprising cannabidiol and/or tetrahydrocannabinol for the treatment of chronic pain

Country Status (8)

Country Link
US (2) US20210346310A1 (https=)
EP (1) EP4110325A4 (https=)
JP (1) JP2023523155A (https=)
CN (1) CN115916184A (https=)
AU (1) AU2021259495A1 (https=)
CA (1) CA3178878A1 (https=)
MX (1) MX2022012415A (https=)
WO (1) WO2021214545A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4041209A4 (en) 2019-10-11 2024-01-24 Pike Therapeutics, Inc. TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS
CA3155181A1 (en) 2019-10-14 2021-04-22 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal delivery of cannabidiol
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
WO2022003623A1 (en) * 2020-07-01 2022-01-06 Pike Therapeutics, Inc. Transdermal pharmaceutical formulations for the treatment of multiple sclerosis
CN117337174A (zh) * 2020-12-03 2024-01-02 长矛治疗股份有限公司 用于治疗癌症的包含cbd或thc的透皮药物制剂
AU2022257344A1 (en) * 2021-04-12 2023-10-26 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
CN117545478A (zh) * 2021-04-22 2024-02-09 长矛治疗股份有限公司 用于治疗慢性疼痛的透皮药物制剂
EP4366728A4 (en) * 2021-07-08 2025-05-14 Innocan Pharma Ltd. COMPOSITIONS FOR THE TREATMENT OF DIABETIC SYMPTOMS
WO2023012691A1 (en) * 2021-08-03 2023-02-09 Pike Therapeutics, Inc. Transdermal micro-dosing delivery of pharmaceutical agents
EP4426290A4 (en) * 2021-11-02 2025-10-08 Schedule 1 Therapeutics Inc USE OF CANNABINOID COMPOSITIONS TO TREAT PAIN ASSOCIATED WITH SMALL FIBER NEUROPATHY
EP4558135A1 (en) * 2022-07-21 2025-05-28 Pike Therapeutics Inc. Continuous delivery systems comprising a cannabinoid and medicinal uses thereof
US11826342B1 (en) * 2022-09-27 2023-11-28 Saaransh Mahna Cannabidiol formulation for alleviating pain and a method of manufacturing
CN118045221B (zh) * 2024-02-04 2024-07-19 广东云曌医疗科技有限公司 一种水凝胶敷料及其制备方法和应用
WO2026018119A1 (en) * 2024-07-16 2026-01-22 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2414933B (en) * 2004-06-08 2009-07-15 Gw Pharma Ltd Cannabinoid compositions for the treatment of disease and/or symptoms in arthritis
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
DK2176208T3 (en) * 2007-07-30 2015-04-27 Zynerba Pharmaceuticals Inc Prodrugs of cannabidiol, compositions containing prodrugs of cannabidiol and methods of use thereof
CA2760460C (en) * 2009-04-28 2019-04-02 Alltranz Inc. Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same
EP2424568A1 (en) * 2009-04-29 2012-03-07 University Of Kentucky Research Foundation Cannabinoid-containing compositions and methods for their use
PT2473475T (pt) * 2009-08-31 2017-08-02 Zynerba Pharmaceuticals Inc Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas
AT509000B1 (de) * 2009-10-23 2012-12-15 Rausch Peter Wasserlösliche zubereitungen von cannabinoiden und cannabispräparaten und deren anwendungen
US9408802B1 (en) * 2012-03-22 2016-08-09 Prosolus, Inc. Seven day drug in adhesive transdermal delivery
US9095563B2 (en) * 2013-09-26 2015-08-04 Ronald D. Sekura Topical treatments incorporating Cannabis sp. derived botanical drug product
US20160022627A2 (en) * 2014-04-18 2016-01-28 Mary's Medicinals LLC Transdermal cannabinoid patch
US9375417B2 (en) * 2014-12-04 2016-06-28 Mary's Medicinals LLC Transdermal cannabinoid formulations
CA2976004C (en) * 2015-02-05 2020-06-02 Colorado Can Llc Purified cbd and cbda, and methods, compositions and products employing cbd or cbda
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
US10028919B2 (en) * 2015-03-10 2018-07-24 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
US10272125B2 (en) * 2015-09-14 2019-04-30 Life Tech Global, Llc Transdermal delivery of cannabidiol with other active moieties including cannabinoids
CN108697665A (zh) * 2015-09-30 2018-10-23 乔治·爱德华·霍格 局部镇痛性疼痛缓解制剂、其制备和使用方法
WO2018083695A2 (en) * 2016-11-02 2018-05-11 Tikun Olam Ltd Combination therapies
US10702495B2 (en) * 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
FR3064334B1 (fr) * 2017-03-24 2021-05-14 Dcns Energies Presse-etoupe de traversee etanche d'un orifice d'une cloison
US12357604B2 (en) * 2017-09-22 2025-07-15 Inmed Pharmaceuticals Inc. Topical formulations of cannabinoids and use thereof in the treatment of pain
EP3687527A4 (en) * 2017-09-25 2021-05-26 Canopy Health Innovations COMPOSITIONS OF CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENS AND FLAVONOIDS AND THEIR USES FOR TREATMENT OF INSOMNIA
BR112020014253A2 (pt) * 2018-01-12 2020-12-08 Nutrae, LLC Formulações de canabinóides encapsuladas para administração oral
CA3112583A1 (en) * 2018-07-09 2020-01-16 New Age Nanotech Llc Stabilized formulations of cannabinoid compositions
US20210015740A1 (en) * 2019-03-04 2021-01-21 Michael Harvey Greenspan Topical cannabinoid compositions, delivery systems, and uses for pain relief
US20200360292A1 (en) * 2019-05-16 2020-11-19 Aegis Therapeutics, Llc Oil-soluble drug containing compositions and methods of use thereof

Also Published As

Publication number Publication date
CN115916184A (zh) 2023-04-04
EP4110325A4 (en) 2024-07-03
JP2023523155A (ja) 2023-06-02
US20210346310A1 (en) 2021-11-11
AU2021259495A1 (en) 2022-10-27
EP4110325A1 (en) 2023-01-04
US20250248948A1 (en) 2025-08-07
MX2022012415A (es) 2023-02-09
WO2021214545A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
US20250248948A1 (en) Transdermal and/or Topical, Pharmaceutical Formulations Comprising Cannabidiol and/or Tetrahydrocannabinol for the Treatment of Chronic Pain
US20220047525A1 (en) Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids
US20260076921A1 (en) Transdermal Pharmaceutical Formulations for the Treatment of Multiple Sclerosis
US12186280B2 (en) Pharmaceutical composition and method for treating seizure disorders
CN114555068A (zh) 大麻二酚的透皮给药
US12121617B2 (en) Transdermal delivery of cannabidiol
US20210251918A1 (en) Pharmaceutical composition and method for treating seizure disorders
US20220347151A1 (en) Transdermal pharmaceutical formulations for the treatment of chronic pain
CA3213953A1 (en) Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) Transdermal delivery of tetrahydrocannabinol
US20250049821A1 (en) Pharmaceutical Composition and Method for Treating Seizure Disorders
WO2026018119A1 (en) Transdermal delivery of tetrahydrocannabinol
CA3214228A1 (en) Transdermal delivery of cannabidiol

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250410

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20250410

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250410

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - SMALL

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250516

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250516

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250516

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250520

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250521

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260408